Brief: Orchard Therapeutics Announces Presentation Of Clinical Proof-Of-Concept For Otl-300
15/04/2019 16:14
April 15 (Reuters) - Orchard Therapeutics PLC ORTX.O :
* ORCHARD THERAPEUTICS ANNOUNCES PRESENTATION OF CLINICAL
PROOF-OF-CONCEPT FOR OTL-300 FOR THE TREATMENT OF
TRANSFUSION-DEPENDENT BETA-THALASSEMIA AT THE 22ND AMERICAN
SOCIETY OF GENE & CELL THERAPY ANNUAL MEETING
* ORCHARD THERAPEUTICS PLC - PRIMARY ENDPOINT OF TRANSFUSION
REDUCTION WAS ACHIEVED AFTER ONE YEAR OF FOLLOW-UP IN EIGHT OUT
OF NINE TDT PATIENTS
* ORCHARD THERAPEUTICS PLC - PATIENTS MET SAFETY ENDPOINTS
WITH NO
ADVERSE EVENTS RELATED TO THERAPY.
Source text for Eikon: ID:nGNX7bkyfk
Further company coverage: ORTX.O
(Reuters.Briefs@thomsonreuters.com)
Recent news on Orchard Therapeutics
See all newsBrief: Orchard Therapeutics Says Court Of Justice Of England & Wales Sanctioned Scheme Of Arrangement Providing For Acquisition Of Co By Kyowa Kirin Co's Unit
Brief: Orchard Therapeutics Receives U.S. FDA Fast Track Designation For OTL-203 In MPS-IH
Brief: Orchard Therapeutics Says U.S. FDA Advised Co It Does Not Intend To Schedule Advisory Committee Meeting
Orchard Therapeutics rises on buyout deal by Japanese drugmaker
Kyowa Kirin to acquire Orchard Therapeutics for $478 mln